Lexaria Bioscience Corp. (CSE:LXX; OTCBB:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e. fat soluble) and difficult for the human gastrointestinal system to efficiently and effectively absorb. DehydraTECH™ greatly improves the body’s ability to absorb these substances so their benefits can be received more quickly and pleasantly.
Lexaria has multiple patents issued or pending in over 40 countries around the world.
Lexaria Bioscience Corp. evolved into its current form in 2014 upon controlling acquisition of the former company where Lexaria’s DehydraTECH™ technology originated. Since then, Lexaria has…